Maastricht, 20-01-2025

The journey toward sustainable healthcare has taken a significant step forward with the development of the Mediclose Cartridge System, an innovative approach to incision closure in laparoscopic surgery.

Our Mediclose team recently had the pleasure of visiting our incredible partner, Assut Europe, in beautiful Rome.

Today marks the successful launch of the OP-Zuid project STIM-00953, “Laprixa, the Intra-operative Predictor of Wound Healing Capacity”!

Corporis Medical CSO Dr. Alexander Veenhof has successfully completed the first in vivo test for our latest innovation, “the miniaturized Laprixa probe”.

This past Tuesday, the Corporis Medical team attended TEFAF Maastricht, courtesy of Brightlands.

After extensive review of Corporis Medical’s 510(k) pre-market submission, the FDA has granted its approval for the Mediclose System to enter the US market!

Led by our CSO and founder Alexander Veenhof, Corporis Medical’s Mediclose System has been validated in patients in a multicenter First-in-Human clinical investigation.

Corporis Medical completed an all equity financing round, including the conversion of existing convertible loans.

EIT Health awards Corporis Medical's “Objective surgical wound healing indicator” with the Quality Label.